GLP-1 for Teens: Which Medicines Are Approved at 12 Plus
Families searching for GLP-1 for teens usually want one clear answer first: which of these medicines is actually approved for adolescents, and which are adult only. This page gives that answer from the labels, then explains why these decisions are led by the family and a clinician together, with growth and nutrition kept in view. It is education only, not a recommendation for any individual teenager.
The headline answer: Wegovy at 12 and older
Wegovy is the GLP-1 medicine whose label includes adolescents. It is approved for adolescents aged 12 and older with obesity, as an addition to a reduced calorie diet and increased physical activity, for chronic weight management. That approval matters because it was based on study in this age group and comes with label instructions written for adolescent use, rather than an adult label being borrowed informally.
Approval for adolescents is narrower than the adult approval in an important way: the label frames it around obesity in this age group, judged by a clinician using measures appropriate for a growing body, rather than around cosmetic weight loss or a number a family picks for itself. Whether a particular teenager fits the label is a clinical judgment made after examination and history, and it is the first question to settle at an appointment, before any discussion of starting.
What adult labels on the other brands mean
The other well known brands in this class, including Ozempic, Mounjaro and Zepbound, carry adult labels: their approved uses were studied and licensed in adults. An adult label does not contain adolescent instructions, and families should be cautious of any route that treats an adult medicine as interchangeable for a teenager simply because the ingredient family is similar. The approved adolescent option exists precisely so that treatment, when it is used, follows a studied path.
This distinction also affects where care should happen. Prescribing for an adolescent belongs with a clinician who treats young people and knows the relevant label, often alongside the family doctor or a pediatric specialist. If a source offers these medicines for a teenager without a proper consultation, medical history and follow up plan, that is a warning sign about the source, whatever brand name it uses. Legitimate treatment starts with eligibility, not with a checkout.
Why decisions are family and clinician led
Treating obesity in adolescence is never just about a medicine. A clinician will usually look at growth history, overall health, other conditions, medicines already being taken, sleep, activity, eating patterns and emotional wellbeing, and will talk about what lifestyle support sits alongside any prescription. Parents or guardians are part of that picture, and so is the teenager, whose own view of treatment, injections and follow up should be heard and taken seriously.
Families can expect the conversation to cover alternatives and timing as well as the medicine itself: what has already been tried, what support is available, what success would realistically look like over months rather than weeks, and how treatment will be reviewed. A good decision may be to start, to wait, or to focus on other measures first. Any of those can be the right answer for a particular teenager, and pressure in either direction, from marketing or from anxiety, is a poor substitute for that assessment.
Growth and nutrition cautions, in words
Adolescence is a period of active growth, and that shapes the cautions around any appetite reducing medicine. These medicines reduce how much a person wants to eat, sometimes sharply. For a still growing teenager, eating too little can mean missing protein, calcium, iron and other nutrients that growth, bone development and concentration at school depend on. This is why nutritional follow up is not an optional extra in adolescent treatment: a clinician or dietitian should keep an eye on whether the teenager is still eating enough of the right things.
Growth itself also needs watching. Height, weight and development are tracked over time in ordinary adolescent care, and that monitoring becomes part of treatment review: is growth continuing as expected, is weight change proportionate, and how is the teenager feeling day to day? Side effects that are merely unpleasant for an adult, such as persistent nausea or repeatedly skipping meals, carry extra weight in a teenager. Report them early rather than treating them as the price of progress.
Daily life: school, sport and support
Practical planning helps treatment fit real life. Weekly injections need a calm routine at home. Appetite changes affect school lunches, sports training and family meals, and teenagers often need help planning smaller, protein containing meals they will actually eat rather than skipping food entirely. Families who treat this as a shared logistics problem, with the teenager involved in the choices, usually manage the routine better than those who treat it as willpower.
Emotional support deserves equal planning. Teenagers can be sensitive about weight, about being seen as different, and about comments from peers, and a medicine does not remove any of that. Keep the focus at home on health, strength, sleep and energy rather than appearance. If mood, body image or eating attitudes become a concern at any point, raise it with the treating clinician promptly. Knowing when to pause and reassess is part of responsible treatment, not a failure of it.
Questions to take to the appointment
Families often find it helps to arrive with a short list: Is my teenager eligible under the adolescent label? What assessments happen before any decision? What eating and activity support comes with treatment? How will growth and nutrition be monitored, and how often? What side effects should prompt a call? And where is the dosing information set out, so we can read the label together? On that last point, dosing details for adolescents live in the Wegovy prescribing information, and the prescriber works from it; this page deliberately points you to the label rather than reproducing a schedule to follow at home.
Finally, keep expectations anchored. Adolescent treatment is a long term health project supervised over months and years, with reviews, adjustments and possibly a decision to stop. The families who do best with it tend to be those who chose it carefully, with a clinician they trust, full information about the label, and support arranged around the teenager. Use this page to prepare for that conversation, not to replace it.
Frequently asked questions
Which GLP-1 medicine is approved for teenagers?
Wegovy is approved for adolescents aged 12 and older with obesity, alongside a reduced calorie diet and increased physical activity. The other well known brands in this class, including Ozempic, Mounjaro and Zepbound, carry adult labels. Eligibility for any individual teenager is judged by a clinician.
Can a teenager use Ozempic or Zepbound instead?
Those brands are labeled for adults, and their labels do not contain adolescent instructions. Families should be cautious of any source that treats adult medicines as interchangeable for teenagers. Where adolescent treatment is appropriate, the studied and labeled route is the one a clinician will discuss with you.
Does a teenager still need to eat properly on these medicines?
Yes, and it matters more, not less, during growth. Appetite falls on these medicines, so protein and key nutrients can be missed if meals are simply skipped. Nutritional follow up, and monitoring of growth over time, are a standard part of responsible adolescent treatment.
Who decides whether a teen starts a GLP-1 medicine?
The decision is led by the family and a clinician together, after assessment of eligibility, health, growth, other conditions and the support available. It may be to start, to wait, or to use other measures first. No website, including this one, can make that decision for an individual teenager.
Where can I read the dosing information for adolescents?
Dosing information for adolescents is set out in the Wegovy prescribing information, published on DailyMed, and the prescriber works directly from the label. This page points you to the label rather than reproducing dosing details, because dose decisions belong with the treating clinician.